Tag Archives: Impella

Impella

Impella and Adverse Events

Impella and Adverse Events

Long after AHA 2019 had presented observational studies showing adverse events associated to Impella, JAMA is finally publishing the official results including all charts and small print.  The controversial analysis of the American registry had suggested worse outcomes with the intravascular microaxial left ventricular assist device Impella vs. the intra-aortic balloon pump in acute myocardial

Impella

Impella: A Revolutionary Device Being Questioned

Observational studies (with their subsequent limitations) show a possible increase in adverse events and costs with the use of the Impella device. Two large observational studies stirred doubts regarding the good performance of new circulatory support devices in real-world daily clinical practice. There were more adverse events, including in-hospital death and major bleeding, and more

AHA 2018 | El dispositivo Impella gana evidencia, pero hacen faltan estudios más grandes

AHA 2018 | More Evidence for the Impella Device, But Larger Trials Are Necessary

In this pilot study, unloading the left ventricle with the Impella CP circulatory support device and delaying angioplasty by about 30 minutes appeared to be feasible and safe in patients with acute myocardial infarction without cardiogenic shock. This work sought to test the hypothesis that the device reduces ischemia-reperfusion injury. The trial included 50 patients who had the

El Impella otorga seguridad en la ATC del TCI no protegido de alto riesgo

Impella Improves Safety in High Risk Unprotected Left Main PCI

Courtesy of Dr. Carlos Fava. The incidence of unprotected left main severe stenosis ranges between 4 and 8%, and it’s mostly associated with multivessel disease. The use of left ventricular support devices in high risk unprotected left main PCI is on the rise, but not much information available in this regard. Read also: “Prior assistance

La asistencia previa con Impella 2.5 disminuye la mortalidad a 30 días en el shock cardiogénico por tronco de coronaria izquierda no protegido

Prior assistance with Impella 2.5 lowers 30-day mortality in cardiogenic shock due to unprotected left main coronary artery lesion

Courtesy of Dr. Carlos Fava. The prevalence of cardiogenic shock in acute myocardial infarction (MI) is 7%-10%, and it is associated with high mortality rates. Unfortunately, 0.7% of these cases are a consequence of unprotected left main coronary artery (ULMCA) as MI-culprit lesion. Its evolution is generally disastrous.   Ventricular assist device support and its implementation time may

angioplastía coronaria

Is Impella an option in high-risk angioplasty?

Courtesy of Dr. Carlos Fava. Provitional ventricular assist devices are increasingly used in high-risk angioplasties, particularly those involving unprotected left main coronary artery (LMCA) with defective ventricular functioning. However, so far its true role has not been well-studied.   This study analyzed 127 consecutive patients in the USpella registry from 2008 to 2015. These subjects underwent high-risk

impella_shock_cardiogenico

Infarction in Cariogenic Shock: Prioritizing the Use of Impella Could Improve Survival

This small study suggests the early use of Impella ventricular support device in patients undergoing AMI complicated by cardiogenic shock could help lower mortality rate in this population.   However, study design should moderate our enthusiasm, mainly because of the cost of this device.   Detroit Cardiogenic Shock Initiative has stressed early identification of cardiogenic

Top